drugs.com
May 19, 2008
MONTVALE, N.J., May 16, 2008 /PRNewswire-FirstCall/ -- The Company reported new clinical data for MEM 1414, its lead PDE4 inhibitor, demonstrating the compound's CNS activity in humans. In addition, the Company has nominated MEM 68626 as the lead development candidate from its 5-HT6 antagonist...
[read full story]